Clinical trial NCT01929317: A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
Official title: A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Parkinson Disease
Keywords: Ropinirole
Parkinson's disease
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2013-08-27
Enrollment: 81
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a Phase III, multicentre, randomized, initial double-blind study with subsequent open label phases. The study will havea screening phase (4 weeks), a dose increase effect verification phase (12 weeks), a down titration 1 phase (1 week), a long-term phase (39 weeks), down titration 2 phase (1 to 2 weeks) and a follow up phase. Subjects will be assigned to Ropinirole CR high-dose group or Ropinirole CR maintenance group at a ratio of 3:1. This study is being conducted to evaluate the efficacy (effect of increasing Ropinirole dose from 16 mg/day to 18-24 mg/day) of the Ropinirole CR tablets in early and advanced PD patients who have not achieved an optimal therapeutic response with marketed Ropinirole Immediate release (IR) (15 mg/day) or marketed Ropinirole CR (16 mg/day) formulations.


Eligibility criteria: Inclusion Criteria:

Inclusion criteria at the start of the screening

* Patients who are diagnosed as Parkinson's Disease with severity of the modified Hoehn \& Yahr criteria Stages I-IV.
* 1) Monotherapy subject: Subjects who have never received L-dopa, or subjects who have had prior exposure to L-dopa (up to 450 milligram (mg)/day) for up to 3 months in total and L-dopa treatment has been discontinued, for a minimum of 4 weeks prior to the screening phase. 2) L-dopa adjunct subject: Subjects receiving L-dopa (up to 450 mg/day) for at least 4 weeks prior to the screening phase.
* Patients receiving 15mg/day Ropinirole IR or 16mg/day Ropinirole CR for 4 weeks prior to the screening phase, UPDRS Part III total (on) scores is 10 points or more at screening visit and can expect clinical efficacy by increasing Ropinirole CR.
* Age: 20years or older (at the time of informed written consent)
* Informed consent: Patients who are able to give informed written consent in person. (i.e. patients who are capable of giving informed written consent on their own)
* Sex: Either sex. Women of child-bearing potential will be eligible for inclusion in this study. However they have to have a negative pregnancy test at the screening visit and will have to agree to further pregnancy testing at the time points determined in study assessments and procedures and practice one of the methods of contraception mentioned in the protocol from the screening visit until the end of the follow-up examination - Outpatient status
* corrected QT (QTc) \<450 millisecond (msec) or \<480msec for subjects with Bundle Branch Block. The QTc should be based on single or averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period.
* Liver function tests: Patients with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 2x upper limit of normal (ULN); and Alkaline Phosphatase and bilirubin =\< 1.5xULN (isolated bilirubin \> 1.5ULN is acceptable if bilirubin is fractionated and direct bilirubin \< 35%) at the screening visit.

Randomization Criteria

* Patients whose UPDRS Part III total (on) scores is 10 points or more at week 0
* Patients who did not achieve an optimal therapeutic response by treatment with 16mg/day Ropinirole CR and required higher dose of Ropinirole CR
* Patients who are 80% or more compliant taking study drug

Exclusion Criteria

* Late stage advanced patients demonstrating incapacitating peak dose or biphasic dyskinsia on their stable dose of L-dopa.
* Patients who have used any other dopamine agonist (except for Ropinirole IR and CR) within 4 weeks prior to the screening phase.
* Patients who have been treated with the following drugs at 4 weeks or earlier before the start of the screening phase, and whose treatment regimen of the drug has been changed. Anticholinergic agents: trihexyphenidyl hydrochloride, piroheptine hydrochloride, mazaticol hydrochloride, metixene hydrochloride, biperiden hydrochloride, profenamine, amantadine hydrochloride,droxidopa, citicoline, selegiline hydrochloride, entacapone, zonisamide, Estrogens, CYP1A2 inhibitors.
* Patients who have been changing in smoking habit (started or stopped smoking) within the screening phase.
* Patients who have been treated with any other investigational drug within 12 weeks prior to the screening phase.
* Patients who present serious physical signs and symptoms other than those of the PD (e.g. cardiac/hepatic/renal disorder and haematopoietic disorder).
* Patients with symptomatic postural hypotension. (e.g. dizziness and syncope).
* Patients with a current or history of drug abuse or alcoholism.
* Patients with severe dementia such as score 3 or 4 of the UPDRS item 1 (Mentation, behaviour, and mood).
* Patients with current or history of major psychosis (e.g. schizophrenia or psychotic depression) such as score 3 or 4 of the UPDRS item 2 (thought disorder) or item 3(depression).
* Patients who have received surgical treatment for PD in the past (e.g. pallidectomy, deep brain stimulation).
* Female patients who are pregnant or lactating, who may be pregnant, or who plan for pregnancy during the study or within 30 days after the last dose of the study drug.
* Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulapathy, hypoalbuminaemia, oesophageal or gastric varices or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Chronic hepatitis B administered immunosuppressive agents due to risk of hapatitis B reactivation.
* Patients with a history of drug allergy to Ropinirole hydrochloride.
* Except for patients with a history of basal cell carcinoma, patients with a current or history of cancer or malignant tumor within 5 years prior to the screening phase.
* Others whom the investigator (subinvestigator) considers ineligible for the study.

Primary outcomes:
measure: Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at Week 12 in the CR High-dose Group
timeFrame: Baseline and Week 12
Secondary outcomes:
measure: Mean Change From Baseline (Week 0) in UPDRS Part III Total Score at the Indicated Visits
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in the Dose Increase Effect Verification Phase
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Dose Increase Effect Verification Phase
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Percent Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Percent Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Dose Increase Effect Verification Phase
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Percent Change From Baseline in the Japanese UPDRS Part 3 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Percent Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Dose Increase Effect Verification Phase
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Long-term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Mean Change From Baseline in UPDRS Part 3 Total Score at the Indicated Visits for Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49, 52
measure: Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Percent Change From Baseline in the Japanese UPDRS Part 1 Total Score at the Indicated Visits in the Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Percent Change From Baseline in the Japanese UPDRS Part 2 Total Score at the Indicated Visits by the on/Off Status in the Long-term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Percent Change From Baseline in the Japanese UPDRS Part 3 Total Score at the Indicated Visits in the Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Percent Change From Baseline in the Japanese UPDRS Part 4 Total Score at the Indicated Visits in the Long-term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Change From Baseline in the Actual Hours of Awake Time Spent "Off" at the Indicated Visits Only in Participants Who Received L-dopa Adjunct
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Change From Baseline in the Percentage of Awake Time Spent "Off" at the Indicated Visits Only in Participants Who Received L-dopa Adjunct
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Change From Baseline in Actual Hours of Awake Time Spent "On" at the Indicated Visits Only in Participants Who Received L-dopa Adjunct
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Change From Baseline in Actual Hours of Awake Time Spent "On"Without Troublesome Dyskinesias at the Indicated Visits Only in Participants Who Received L-dopa Adjunct
timeFrame: Baseline, Weeks, 2, 4, 6, 8 and 12
measure: Number of Participants With an Improvement (Responder) in the Clinical Global Impression (CGI) Global Improvement Scale at Week 12
timeFrame: Week 12
measure: Number of Participants Remaining in the Study
timeFrame: From the start of the study medication (Week 0) until Week 52
measure: Number of Participants Achieving a 30% and 20% Reduction From Baseline in the UPDRS Total Part 3 Score at the Indicated Visits in Long Term Phase.
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49, 52
measure: Change From Baseline in the Actual Hours of Awake Time Spent "Off" at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Change From Baseline in the Percentage of Awake Time Spent "Off" at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Change From Baseline in Actual Hours of Awake Time Spent "On" at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Change From Baseline in Actual Hours of Awake Time Spent "On" Without Troublesome Dyskinesias at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Change From Baseline in Percentage of Awake Time Spent "On" at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
measure: Change From Baseline in Percentage of Awake Time Spent "On" Without Troublesome Dyskinesias at the Indicated Visits Only in Participants Who Received L-dopa Adjunct in Long Term Phase
timeFrame: Baseline (Week 13), Weeks 17, 21, 25, 37, 49 and 52
Other outcomes:
Locations:
city: Aichi
country: Japan
facility: GSK Investigational Site
city: Akita
country: Japan
facility: GSK Investigational Site
city: Aomori
country: Japan
facility: GSK Investigational Site
city: Hokkaido
country: Japan
facility: GSK Investigational Site
city: Hokkaido
country: Japan
facility: GSK Investigational Site
city: Hyogo
country: Japan
facility: GSK Investigational Site
city: Hyogo
country: Japan
facility: GSK Investigational Site
city: Iwate
country: Japan
facility: GSK Investigational Site
city: Iwate
country: Japan
facility: GSK Investigational Site
city: Kagawa
country: Japan
facility: GSK Investigational Site
city: Kanagawa
country: Japan
facility: GSK Investigational Site
city: Kyoto
country: Japan
facility: GSK Investigational Site
city: Okayama
country: Japan
facility: GSK Investigational Site
city: Osaka
country: Japan
facility: GSK Investigational Site
city: Osaka
country: Japan
facility: GSK Investigational Site
city: Shizuoka
country: Japan
facility: GSK Investigational Site
city: Shizuoka
country: Japan
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References:
citation: Hattori N, Hasegawa K, Sato K, Mitsuyama E, Numachi Y. Clinical evaluation of ropinirole controlled-release formulation at 18-24 mg/day in Japanese patients with Parkinson's disease. Parkinsonism Relat Disord. 2017 Jul;40:33-39. doi: 10.1016/j.parkreldis.2017.04.005. Epub 2017 Apr 13.